Sansure Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Sansure Biotech has a total shareholder equity of CN¥7.4B and total debt of CN¥409.8M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are CN¥8.6B and CN¥1.2B respectively. Sansure Biotech's EBIT is CN¥41.2M making its interest coverage ratio -0.5. It has cash and short-term investments of CN¥4.6B.
Key information
5.6%
Debt to equity ratio
CN¥409.76m
Debt
| Interest coverage ratio | -0.5x |
| Cash | CN¥4.57b |
| Equity | CN¥7.35b |
| Total liabilities | CN¥1.22b |
| Total assets | CN¥8.57b |
Recent financial health updates
Recent updates
Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit
Nov 03
Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings
Oct 09Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital
Oct 03Is Sansure Biotech (SHSE:688289) A Risky Investment?
Sep 12Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected
Aug 21Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28Financial Position Analysis
Short Term Liabilities: 688289's short term assets (CN¥5.7B) exceed its short term liabilities (CN¥714.3M).
Long Term Liabilities: 688289's short term assets (CN¥5.7B) exceed its long term liabilities (CN¥503.8M).
Debt to Equity History and Analysis
Debt Level: 688289 has more cash than its total debt.
Reducing Debt: 688289's debt to equity ratio has increased from 0% to 5.6% over the past 5 years.
Debt Coverage: 688289's debt is well covered by operating cash flow (49.6%).
Interest Coverage: 688289 earns more interest than it pays, so coverage of interest payments is not a concern.